[{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Cutaneous Patch","sponsorNew":"University Hospital, Clermont-Ferrand \/ Grunenthal","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Clermont-Ferrand \/ Grunenthal"},{"orgOrder":0,"company":"Biotechnology Institute IMASD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Plasma Rich In Growth Factors","moa":"Growth factor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Biotechnology Institute IMASD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intervertebral","sponsorNew":"Biotechnology Institute IMASD \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Biotechnology Institute IMASD \/ Inapplicable"},{"orgOrder":0,"company":"Promomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ethyl Methyl Hydroxypyridine Succinate","moa":"Free radicals","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Promomed \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Promomed \/ Inapplicable"},{"orgOrder":0,"company":"Promomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ethyl Methyl Hydroxypyridine Succinate","moa":"Free radicals","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Promomed \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Promomed \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Allergan Aesthetics","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Allergan Aesthetics"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"Insud Pharma","sponsor":"Chemo Research","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Drospirenone","moa":"Mineralocorticoid receptor | Progesterone receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Insud Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"Insud Pharma \/ Chemo Research","highestDevelopmentStatusID":"11","companyTruncated":"Insud Pharma \/ Chemo Research"},{"orgOrder":0,"company":"Lindenhofgruppe AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Lindenhofgruppe AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lindenhofgruppe AG \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Lindenhofgruppe AG \/ Inapplicable"},{"orgOrder":0,"company":"Kyung Hee University Hospital at Gangdong","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evogliptin","moa":"Dipeptidyl peptidase IV","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Kyung Hee University Hospital at Gangdong","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyung Hee University Hospital at Gangdong \/ Dong-A ST Co., Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Kyung Hee University Hospital at Gangdong \/ Dong-A ST Co., Ltd."},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alendronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Peking Union Medical College Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"Type-1 angiotensin II receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risedronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dong-A ST Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Dong-A ST Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Jiaotong University Affiliated Sixth People's Hospital","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Shanghai Jiaotong University Affiliated Sixth People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shanghai Jiaotong University Affiliated Sixth People's Hospital \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Jiaotong University Affiliated Sixth People's Hospital \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"Illumination Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Metaxalone","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Primus Pharmaceutical \/ Illumination Health","highestDevelopmentStatusID":"11","companyTruncated":"Primus Pharmaceutical \/ Illumination Health"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"Type-1 angiotensin II receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"WellSpan Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"WellSpan Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"WellSpan Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"WellSpan Health \/ Inapplicable"},{"orgOrder":0,"company":"Shandong University","sponsor":"Qianfoshan Hospital | Chenland Nutritionals | Jinan Hetai Pharmaceutical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Ucommia Ulmoides Extract","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Shandong University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shandong University \/ Qianfoshan Hospital | Chenland Nutritionals | Jinan Hetai Pharmaceutical Technology","highestDevelopmentStatusID":"11","companyTruncated":"Shandong University \/ Qianfoshan Hospital | Chenland Nutritionals | Jinan Hetai Pharmaceutical Technology"},{"orgOrder":0,"company":"Qiang Fu","sponsor":"Yangtze River Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Zhengyuan","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Qiang Fu","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Qiang Fu \/ Yangtze River Pharmaceutical Group","highestDevelopmentStatusID":"11","companyTruncated":"Qiang Fu \/ Yangtze River Pharmaceutical Group"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNX80","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"SK Chemicals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"SK Chemicals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hospital for Special Surgery, New York","sponsor":"Radius Health | Crozer-Keystone Health System","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Hospital for Special Surgery, New York","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hospital for Special Surgery, New York \/ Radius Health | Crozer-Keystone Health System","highestDevelopmentStatusID":"11","companyTruncated":"Hospital for Special Surgery, New York \/ Radius Health | Crozer-Keystone Health System"},{"orgOrder":0,"company":"James J. Peters Veterans Affairs Medical Center","sponsor":"Kessler Institute for Rehabilitation","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"James J. Peters Veterans Affairs Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"James J. Peters Veterans Affairs Medical Center \/ Kessler Institute for Rehabilitation","highestDevelopmentStatusID":"11","companyTruncated":"James J. Peters Veterans Affairs Medical Center \/ Kessler Institute for Rehabilitation"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KRN23","moa":"Fibroblast growth factor 23","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"University of Louisville","sponsor":"BioHorizons","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Putty Bone Allograft","moa":"Bone regeneration","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"University of Louisville","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Louisville \/ BioHorizons","highestDevelopmentStatusID":"11","companyTruncated":"University of Louisville \/ BioHorizons"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein type IV alpha subunit","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"Epitech Group SpA","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Epitech Group SpA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Granules","sponsorNew":"Epitech Group SpA \/ Azienda Ospedaliera Universitaria Integrata Verona","highestDevelopmentStatusID":"11","companyTruncated":"Epitech Group SpA \/ Azienda Ospedaliera Universitaria Integrata Verona"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Baui Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Z-Brace","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Taiwan University Hospital \/ Baui Biotech","highestDevelopmentStatusID":"11","companyTruncated":"National Taiwan University Hospital \/ Baui Biotech"},{"orgOrder":0,"company":"Temple University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Temple University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Temple University \/ Merck & Co"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Alberta Health services | Alberta Hip and Knee Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Alberta Health services | Alberta Hip and Knee Clinic","highestDevelopmentStatusID":"11","companyTruncated":"University of Calgary \/ Alberta Health services | Alberta Hip and Knee Clinic"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ Merck & Co"},{"orgOrder":0,"company":"Casey Stondell","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Casey Stondell","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Casey Stondell \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"Casey Stondell \/ Pacira BioSciences"},{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"Plateforme d\u2019Investigation Clinique, INSERM CIC1405 | Fondation Apicil | M\u00e9decine Physique et R\u00e9adaptation, CHU de Clermont-Ferrand | M\u00e9decine du Sport, CHU Clermont-Ferrand | Rhumatologie, CHU de Clermont-Ferrand | Clermont-Ferrand University Hospital | ","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Clermont-Ferrand \/ Plateforme d\u2019Investigation Clinique, INSERM CIC1405 | Fondation Apicil | M\u00e9decine Physique et R\u00e9adaptation, CHU de Clermont-Ferrand | M\u00e9decine du Sport, CHU Clermont-Ferrand | Rhumatologie, CHU de Clermont-Ferrand | Clermont-Ferrand University Hospital | ","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Clermont-Ferrand \/ Plateforme d\u2019Investigation Clinique, INSERM CIC1405 | Fondation Apicil | M\u00e9decine Physique et R\u00e9adaptation, CHU de Clermont-Ferrand | M\u00e9decine du Sport, CHU Clermont-Ferrand | Rhumatologie, CHU de Clermont-Ferrand | Clermont-Ferrand University Hospital | "},{"orgOrder":0,"company":"Xi\u2019an Honghui Hospital","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eldecalcitol","moa":"Vitamin D receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Xi\u2019an Honghui Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xi\u2019an Honghui Hospital \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Xi\u2019an Honghui Hospital \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"University of Missouri-Columbia","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"University of Missouri-Columbia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Missouri-Columbia \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Missouri-Columbia \/ Merck & Co"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"JW Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"HMG-CoA reductase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ JW Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ JW Pharmaceutical"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Duloxetine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sunnybrook Health Sciences Centre \/ Inapplicable"},{"orgOrder":0,"company":"IMMUNOe Research Centers","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Conestat Alfa","moa":"Plasma protease C1 inhibitor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"IMMUNOe Research Centers","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IMMUNOe Research Centers \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"IMMUNOe Research Centers \/ Inapplicable"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Ipsen","highestDevelopmentStatusID":"11","companyTruncated":"Gabrail Cancer Center Research \/ Ipsen"},{"orgOrder":0,"company":"LifeBridge Health","sponsor":"Rubin Institute for Advanced Orthopedics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Fascia Iliaca Nerve Block","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"LifeBridge Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LifeBridge Health \/ Rubin Institute for Advanced Orthopedics","highestDevelopmentStatusID":"11","companyTruncated":"LifeBridge Health \/ Rubin Institute for Advanced Orthopedics"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Skye Biologics Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Activematrix","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Skye Biologics Holdings","highestDevelopmentStatusID":"11","companyTruncated":"Baylor College of Medicine \/ Skye Biologics Holdings"},{"orgOrder":0,"company":"Australian Catholic University","sponsor":"Pendulum Therapeutics | Curtin University","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Pendulum WBF-038","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Australian Catholic University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Australian Catholic University \/ Pendulum Therapeutics | Curtin University","highestDevelopmentStatusID":"11","companyTruncated":"Australian Catholic University \/ Pendulum Therapeutics | Curtin University"},{"orgOrder":0,"company":"University of Texas Health Science Center at Houston","sponsor":"Skye Biologics Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Activematrix","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"University of Texas Health Science Center at Houston","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Health Science Center at Houston \/ Skye Biologics Holdings","highestDevelopmentStatusID":"11","companyTruncated":"University of Texas Health Science Center at Houston \/ Skye Biologics Holdings"},{"orgOrder":0,"company":"Allegheny Singer Research Institute","sponsor":"Connective Tissue Matrix Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Allograft","moa":"Progenitor cell","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Allegheny Singer Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegheny Singer Research Institute \/ Connective Tissue Matrix Biomedical","highestDevelopmentStatusID":"11","companyTruncated":"Allegheny Singer Research Institute \/ Connective Tissue Matrix Biomedical"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"Vanilloid receptor","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Propella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Propella Therapeutics \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Propella Therapeutics \/ Aosaikang Pharmaceutical"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
